JP2005512509A - 癌の処置および検出において有用な１０１ｐ３ａ１１またはｐｈｏｒ−１と名称が与えられる核酸および対応するタンパク質 - Google Patents

癌の処置および検出において有用な１０１ｐ３ａ１１またはｐｈｏｒ−１と名称が与えられる核酸および対応するタンパク質 Download PDF

Info

Publication number
JP2005512509A
JP2005512509A JP2002589708A JP2002589708A JP2005512509A JP 2005512509 A JP2005512509 A JP 2005512509A JP 2002589708 A JP2002589708 A JP 2002589708A JP 2002589708 A JP2002589708 A JP 2002589708A JP 2005512509 A JP2005512509 A JP 2005512509A
Authority
JP
Japan
Prior art keywords
protein
cell
antibody
cancer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512509A5 (fr
Inventor
アヤ ジャコボビツ，
メアリー ファリス，
オーサー ビー． レイタノ，
ロバート ケンドール モリソン，
ダグラス サフラン，
ワンマオ ジーイー，
ピア エム． チャリタ−エイド，
Original Assignee
アジェンシス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/001,469 external-priority patent/US7208280B2/en
Priority claimed from US10/017,066 external-priority patent/US6838258B2/en
Application filed by アジェンシス，インコーポレイテッド filed Critical アジェンシス，インコーポレイテッド
Publication of JP2005512509A publication Critical patent/JP2005512509A/ja
Publication of JP2005512509A5 publication Critical patent/JP2005512509A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002589708A 2001-05-15 2002-05-15 癌の処置および検出において有用な１０１ｐ３ａ１１またはｐｈｏｒ−１と名称が与えられる核酸および対応するタンパク質 Pending JP2005512509A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29111801P 2001-05-15 2001-05-15
US10/001,469 US7208280B2 (en) 1999-10-05 2001-10-31 Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US10/017,066 US6838258B2 (en) 1999-10-05 2001-12-14 G protein-coupled receptor up-regulated in prostate cancer and uses thereof
PCT/US2002/015520 WO2002092842A2 (fr) 2001-05-15 2002-05-15 Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers

Publications (2)

Publication Number Publication Date
JP2005512509A true JP2005512509A (ja) 2005-05-12
JP2005512509A5 JP2005512509A5 (fr) 2005-12-22

Family

ID=38616826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589708A Pending JP2005512509A (ja) 2001-05-15 2002-05-15 癌の処置および検出において有用な１０１ｐ３ａ１１またはｐｈｏｒ−１と名称が与えられる核酸および対応するタンパク質

Country Status (6)

Country Link
EP (1) EP1539805A4 (fr)
JP (1) JP2005512509A (fr)
AU (2) AU2002309873B2 (fr)
CA (1) CA2447564A1 (fr)
IL (1) IL158860A0 (fr)
WO (1) WO2002092842A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
JP5122592B2 (ja) * 2010-01-04 2013-01-16 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
US10722563B2 (en) * 2012-09-20 2020-07-28 Shenzhen Innovation Immunotechnology Co., Ltd. Prostate-specific tumor antigens and uses thereof
CN111549140B (zh) * 2020-06-08 2023-08-08 重庆医科大学附属第一医院 一种检测肺癌相关基因C2orf40、FIBIN和GRP甲基化的试剂盒及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367640T3 (es) * 1996-03-11 2011-11-07 Epimmune Inc. Péptidos con afinidad de unión aumentada para al menos tres moléculas de tipo hla-a3.
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000020590A2 (fr) * 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. Proteines de recepteurs couples a des proteines g
WO2000044775A2 (fr) * 1999-01-27 2000-08-03 Epimmune Inc. Identification d'epitopes de cellules t restreintes au hla et fortement reactives
ATE417104T1 (de) * 1999-10-05 2008-12-15 Agensys Inc G protein-gekoppelter in prostatakrebs hochexprimierter rezeptor und seine verwendungen
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
AU2903701A (en) * 1999-10-08 2001-04-23 Digiscents Olfactory receptor sequences
EP1299528A4 (fr) * 2000-03-13 2005-10-05 Senomyx Inc Nouveaux recepteurs olfactifs humains et genes codant ces recepteurs
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001074904A2 (fr) * 2000-03-31 2001-10-11 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour celles-ci
US20030022237A1 (en) * 2000-09-27 2003-01-30 Feder John N. Novel human G-protein coupled receptor, HGPRBMY4, expressed highly in prostate, colon, and lung
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer

Also Published As

Publication number Publication date
AU2008200363B2 (en) 2010-08-12
EP1539805A2 (fr) 2005-06-15
CA2447564A1 (fr) 2002-11-21
WO2002092842A3 (fr) 2005-04-21
AU2008200363A8 (en) 2008-03-13
AU2008200363A1 (en) 2008-02-21
IL158860A0 (en) 2004-05-12
EP1539805A4 (fr) 2005-11-16
AU2002309873B2 (en) 2007-10-18
WO2002092842A2 (fr) 2002-11-21

Similar Documents

Publication Publication Date Title
JP5787487B2 (ja) 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
US8236510B2 (en) Protein showing enhanced expression in cancer cells
US7928196B2 (en) Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
JP2007254490A (ja) 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
JP2005534287A (ja) 癌の処置および検出において有用な９８ｐ４ｂ６との名称の核酸および対応するタンパク質
JP2006513724A (ja) 癌の処置および検出において有用な１９１Ｐ４Ｄ１２（ｂ）と称される、核酸および対応タンパク質
JP2010110325A (ja) 癌の処置および検出において有用な１９３ｐ１ｅ１ｂと称される、核酸および対応タンパク質
JP2011152132A (ja) 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
AU2007201445B2 (en) Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
AU2008200363B2 (en) Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer
US8039603B2 (en) Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US7510840B1 (en) Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody
AU2002309873A1 (en) Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer
JP2007244383A (ja) 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質
JP2006508163A (ja) 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
CA2480811A1 (fr) Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
JP5122592B2 (ja) 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
US8647826B2 (en) Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US20120076789A1 (en) Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
IL158860A (en) 101p3a11 peptides for use in vaccine preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080212

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080813

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081016

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20081107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110217